Literature DB >> 12821736

Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study.

C T Trott1, S Fahn, P Greene, S Dillon, H Winfield, L Winfield, R Kao, D Eidelberg, C R Freed, R E Breeze, Y Stern.   

Abstract

OBJECTIVES: To determine if bilateral transplantation of embryonic mesencephalic dopamine cells into the putamen of patients with PD significantly affected their cognitive functioning when compared with patients receiving sham surgery and to examine the effect of age on cognitive performance after implantation.
METHODS: Forty patients (19 women, 21 men; age 34 to 75 years) with idiopathic PD of at least 7 years' duration (mean 14 years) who had disabling motor signs despite optimal drug management were randomly assigned to tissue implants or sham craniotomies in a double-blind design. Neuropsychological tests assessing orientation, attention, language, verbal and visual memory, abstract reasoning, executive function, and visuospatial and construction abilities were administered before and 1 year after surgery. Treatment groups did not differ at baseline in demographic, neuropsychological, motor, depression, or levodopa equivalent measures.
RESULTS: Postsurgical change in cognitive performance was not significantly different for real or sham surgery groups. Performance in both groups remained unchanged at follow-up for most measures.
CONCLUSIONS: Embryonic dopamine producing neurons can be implanted safely into the putamen bilaterally without impairing cognition in patients with PD, but within the first year, improved cognition should not be expected.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821736     DOI: 10.1212/01.wnl.0000070181.28651.3b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Minority enrollment in Parkinson's disease clinical trials.

Authors:  Myra G Schneider; Christopher J Swearingen; Lisa M Shulman; Jian Ye; Mona Baumgarten; Barbara C Tilley
Journal:  Parkinsonism Relat Disord       Date:  2008-08-09       Impact factor: 4.891

Review 2.  Dopamine cell transplantation in Parkinson's disease: challenge and perspective.

Authors:  Yilong Ma; Shichun Peng; Vijay Dhawan; David Eidelberg
Journal:  Br Med Bull       Date:  2011-08-28       Impact factor: 4.291

3.  Purified mouse dopamine neurons thrive and function after transplantation into brain but require novel glial factors for survival in culture.

Authors:  A E Donaldson; C E Marshall; Ming Yang; S Suon; Lorraine Iacovitti
Journal:  Mol Cell Neurosci       Date:  2005-09       Impact factor: 4.314

Review 4.  Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials.

Authors:  Curt R Freed; Wenbo Zhou; Robert E Breeze
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

5.  Video Review of Baseline Performance on Global Ratings in a Double-Blind Placebo Surgery Trial.

Authors:  Cynthia McRae; Jennifer Caspari; Daniel Russell; Heiner Ellgring; Chris Bezzant; Paul Greene; Stanley Fahn
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

6.  Defining the unknowns for cell therapies in Parkinson's disease.

Authors:  Emma L Lane; Mariah J Lelos
Journal:  Dis Model Mech       Date:  2022-09-27       Impact factor: 5.732

7.  The therapeutic potential of stem cells and progenitor cells for the treatment of Parkinson's disease.

Authors:  Mooi Tiong Liau; Farahnaz Amini; Thamil Selvee Ramasamy
Journal:  Tissue Eng Regen Med       Date:  2016-10-20       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.